natgillin/translations-raw huggingface dataset:
If you take more Cozaar than you should
Če ste vzeli večji odmerek zdravila Cozaar, kot bi smeli
The combination of losartan with a beta-blocker should be used with caution”.
Kombinacijo losartana in zaviralca beta je treba uporabljati previdno.“
Symptoms of intoxication
Simptomi zastrupitve
Cozaar 12.5 mg, 25 mg, 50 mg and 100 mg contain potassium in the following amounts: 1.06 mg (0.027 mEq), 2.12 mg (0.054 mEq), 4.24 mg (0.108 mEq) and 8.48 mg (0.216 mEq) respectively.
Cozaar 12,5 mg, 25 mg, 50 mg oz. 100 mg tablete vsebujejo kalij v naslednjih količinah: 1,06 mg (0,027 mEq), 2,12 mg (0,054 mEq), 4,24 mg (0,108 mEq) oz. 8,48 mg (0,216 mEq).
BATCH NUMBER
ŠTEVILKA SERIJE Batch:
Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients.
Losartan je enako učinkovit pri zdravljenju bolnikov s hipertenzijo moškega in ženskega spola, tako mlajših (mlajših od 65 let) kot starejših.
Take particular care if you are taking the following medicines while under treatment with Cozaar:
Še posebej pozorni bodite, če med zdravljenjem z zdravilom Cozaar jemljete katero od naslednjih zdravil:
The observation of the ELITE I Study, that, compared with captopril, Losartan reduced the mortality risk, was not confirmed in the subsequent ELITE II Study, which is described in the following.
Opažanje iz študije ELITE, da je losartan v primerjavi s kaptoprilom zmanjšal tveganje za smrt, v naslednji študiji ELITE II, ki je opisana v nadaljevanju, ni bilo potrjeno.
This composite endpoint can be considered as representative for CV morbidity and mortality, and has translated into this indication in many medicinal products that have been discussed in the CHMP (e.g. statins).
Ta sestavljeno primarno končno točko je mogoče smatrati za reprezentativno za srčnožilno obolevnost in smrtnost, na tej osnovi pa je bila oblikovana navedena indikacija pri številnih zdravilih, obravnavanih v okviru CHMP (npr. statinih).
Germany MSD Chibropharm GmbH Postfach 1202 D-85530 Haar
MSD Chibropharm GmbH Postfach 1202 D-85530 Haar, Nemčija
The combination of losartan with a beta-blocker should be used with caution (see section 5.1).
Kombinacijo losartana in beta zaviralca je treba previdno uporabljati (glejte poglavje 5.1).
Losartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes, hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).
Losartan lahko tudi odloži napredovanje diabetične nefropatije ter je indiciran tudi za upočasnitev napredovanja ledvične bolezni pri bolniki s sladkorno boleznijo tipa 2, hipertenzijo in mikroalbuminurijo (>30 mg/24 ur) ali proteinurijo (>900 mg/24 ur).
In the treatment of heart failure, losartan is usually combined with a diuretic (medicine that increases the amount of water that you pass out through your kidneys) and/or digitalis (medicine that helps to make the heart stronger and more efficient) and/or a beta-blocker .
Pri zdravljenju srčnega popuščanje se losartan običajno kombinira z diuretikom (zdravilo, ki poveča količino vode, ki se izloči skozi ledvice) in/ali digitalisom (zdravilo, ki pripomore, da je srce močnejše in učinkovitejše) in/ali beta zaviralcem.
At the time of the study, beta-blockade alone, or in combination with diuretics had shown to reduce rates of many CV events by 15-45%.
V času študije je bilo dokazano, da blokada receptorjev beta sama ali v kombinaciji z diuretiki zmanjša pogostost številnih srčnožilnih dogodkov za 15 do 45 %.
Despite these increases, antihypertensive activity and suppression of plasma aldosterone concentration are maintained, indicating effective angiotensin II receptor blockade.
Kljub temu povečanju pa se ohranjata antihipertenzivna aktivnost in zmanjševanje koncentracije aldosterona v plazmi, kar kaže na učinkovito blokado receptorjev za angiotenzin II.
During oncedaily dosing with 100 mg, neither losartan nor its active metabolite accumulates significantly in plasma.
Pri enkrat dnevnem odmerjanju 100 mg se niti losartan niti njegov aktivni presnovek v plazmi ne kopičita pomembno.
When pregnancy is diagnosed, treatment with losartan should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6).
Ko se ugotovi nosečnost, je treba zdravljenje z losartanom takoj prekiniti in, če je primerno, začeti alternativno zdravljenje (glejte poglavji 4.3 in 4.6).
Some patients may receive an additional benefit by increasing the dose to 100 mg once daily (in the morning).
Pri nekaterih bolnikih lahko dodatno korist dosežemo s povečanjem odmerka na 100 mg enkrat na dan (zjutraj).
- Renal protection in patients with Type-2 diabetes and proteinuria The CHMP considered the benefit/risk ratio of this indication is positive.
- Zaščita ledvic pri bolnikih s sladkorno boleznijo tipa 2 in proteinurijo CHMP je bil mnenja, da je razmerje med tveganji in koristmi za to indikacijo pozitivno.
The rise in trough diastolic blood pressure was the same in patients receiving placebo and in those continuing losartan at the lowest dose in each group, again suggesting that the lowest dose in each group did not have significant antihypertensive effect.
Povečanje diastoličneg krvnega tlaka ob izteku učinka je bilo pri bolnikih, ki so prejemali placebo, in pri tistih, ki so nadaljevali z uporabo losartana v najnižjem odmerku, enako v vseh skupinah, kar ponovno nakazuje, da najnižji odmerek v vsaki skupini ni imel pomembnega antihipertenzivnega učinka.
When pregnancy is diagnosed, treatment with losartan should be stopped immediately and, if appropriate, alternative therapy should be started.
Ob potrjeni nosečnosti je treba zdravljenje z losartanom takoj prekiniti, in, če je primerno, začeti alternativno zdravljenje.
LIFE-Study
Študija LIFE
During the referral procedure, the MAH proposed amending the indication to substitute “cardiovascular morbidity and mortality” with “stroke”.
Med postopkom napotitve je imetnik dovoljenja za promet z zdravilom predlagal dopolnitev indikacije tako, da se „srčnožilna obolevnost in smrtnost“ nadomesti s „kapjo“.
The active metabolite is 10- to 40- times more active than Losartan on a weight for weight basis.
Aktivni presnovek je 10- do 40-krat bolj aktiven kot losartan (v isti količini).
The concomitant use of potassium sparing diuretics, potassium supplements and potassium containing salt substitutes with losartan is not recommended (see section 4.5).
Sočasne uporabe diuretikov, ki varčujejo kalij, kalijevih dodatkov in nadomestkov soli, ki vsebujejo kalij, ter losartana ne priporočamo (glejte poglavje 4.5).
- The use of losartan in paediatric patients should be included in sections 4.2, 4.4, 4.8, 5.1 and 5.2 of the SPC, and the relevant sections of the Package Leaflet.
- Uporabo losartana pri pediatričnih bolnikih je treba vključiti v poglavja 4.2, 4.4, 4.8, 5.1 in 5.2 SPC ter v ustrezna poglavja navodila za uporabo.
An increased mortality was observed in ELITE II in the small subgroup (22% of all HF patients) taking beta-blockers at baseline.
Povečano smrtnost so opazili v majhni podskupini bolnikov iz študije ELITE II (22 % vseh bolnikov s srčnim popuščanjem), ki so na začetku jemali beta zaviralce.
Compared to patients with normal renal function, the AUC for Losartan is about 2-times higher in haemodialysis dialysis patients.
V primerjavi z bolniki z normalno ledvično funkcijo je pri bolnikih na hemodializi AUC losartana približno 2-krat večja.
When losartan is administered orally, about 4% of the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the urine as active metabolite.
Po peroralnem odmerku losartana se približno 4 % zaužitega odmerka izloči v urin nespremenjenega, približno 6 % zaužitega odmerka pa v obliki aktivnega presnovka.
The results showed roughly similar pharmacokinetic parameters of losartan following oral administration in infants and toddlers, preschool children, school age children and adolescents.
Rezultati so pokazali približno podobne farmakokinetične parametre za losartan po peroralni uporabi pri dojenčkih in malčkih, predšolskih otrocih, šolarjih in mladostnikih.
There are limited data on the efficacy and safety of losartan in children and adolescents aged 6-16 years old for the treatment of hypertension (see 5.1: Pharmacodynamic properties).
Na voljo je le malo podatkov o učinkovitosti in varnosti losartana pri otrocih in mladostnikih, starih 6 do 16 let, pri uporabi za zdravljenje hipertenzije (glejte 5.1: Farmakodinamične lastnosti).
A recent review in the BMJ shows that specifically the preventive effect on stroke of atenolol is lower than for other antihypertensives; RR of 1.26 (95%CI: 1.15 to 1.38).
Nedavni pregled v BMJ kaže, da je preventivni učinek atenolola glede kapi manjši kot pri drugih antihipertenzivih; relativno tveganje (RR) 1,26 (95-odstotni interval zaupanja (CI): 1,15 do 1,38).
Do not use Cozaar after the expiry date which is stated on the carton after EXP.
Zdravila Cozaar ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake "Uporabno do".
Since then the beneficial effect of atenolol regarding CV morbidity and mortality has been questioned.
Od tedaj je ugoden učinek atenolola v zvezi s srčnožilno obolevnostjo in smrtnostjo pod vprašajem.
ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, POTI UPORABE ZDRAVILA, PREDLAGATELJEV, IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
As a consequence the observed 25% risk reduction with losartan versus atenolol brings the protective effect of losartan on stroke in the same range as for other antihypertensives.
Posledično ugotovljeno 25-odstotno zmanjšanje tveganja pri uporabi losartana v primerjavi z atenololom pomeni zaščitni učinek losartana glede kapi enakega reda velikosti, kot ga imajo drugi antihipertenzivi.
Hypersensitivity to the active substance or to any of the excipients (see section 4.4 and 6.1).
Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov (glejte poglavji 4.4 in 6.1).
Patients with primary aldosteronism generally will not respond to antihypertensive drugs acting through inhibition of the renin-angiotensin system.
Bolniki s primarnim hiperladosteronizmom se na zdravljenje z antihipertenzivi, ki zavirajo sistem renin-angiotenzin, večinoma ne odzovejo.
• low blood pressure,
• nizek krvni tlak
• back pain and urinary track infection.
• bolečine v hrbtu in okužba urinarnega trakta
The proposed indication is based on the results from the RENAAL study, where the effect of losartan was investigated on a composite primary endpoint of renal endpoints and mortality in patients with Type II diabetes mellitus with proteinuria.
Predlagana indikacija temelji na rezultatih študije RENAAL, v kateri so preučevali učinek losartana z ozirom na primarno končno točko, sestavljeno iz ledvičnih pokazateljev in smrtnosti, pri bolnikih s sladkorno boleznijo tipa 2 s proteinurijo.
In female hypertensive patients the plasma levels of losartan were up to twice as high as in male hypertensive patients, while the plasma levels of the active metabolite did not differ between men and women.
Pri ženskah s hipertenzijo so bile koncentracije losartana v plazmi do dvakrat višje kot pri moških s hipertenzijo, količine aktivnega presnovka v plazmi pa se med moškimi in ženskami niso razlikovale.
• if your liver function is impaired (see sections 2 "Do not take Losartan" and 3 ‘Dosage in special patient groups'),
• če imate okvaro jeter (glejte poglavje 2 "Ne jemljite zdravila Cozaar" in poglavje 3 "Odmerjanje pri posebnih skupinah bolnikov").
Doses above 1.4 mg/ kg (or in excess of 100 mg) daily have not been studied in pediatric patients.
Odmerkov nad 1,4 mg/ kg (ali nad 100 mg) dnevno pri pediatričnih bolnikih niso preučevali.
Losartan is predominantly metabolised by cytochrome P450 (CYP) 2C9 to the active carboxy-acid metabolite.
Losartan presnavlja predvsem citokrom P450 (CYP) 2C9 v aktivni karboksikislinski presnovek.
• too less sugar in the blood (hypoglycaemia),
• premalo sladkorja v krvi (hipoglikemija)
Losartan is an orally active angiotensin II (Ang- II) receptor antagonist acting on the AT1 receptor subtype, thus blocking the effect of Ang-II in the renin angiotensin system (RAS) cascade.
Losartan je peroralno aktivni antagonist receptorjev angiotenzina II (Ang- II), delujoč na receptorje podtipa AT1, ki na ta način blokira učinek Ang-II v kaskadi renin-angiotenzinskega sistema (RAS).
In a clinical trial it was found that fluconazole (inhibitor of CYP2C9) decreases the exposure to the active metabolite by approximately 50%.
V kliničnem preizkušanju so ugotovili, da flukonazol (zaviralec CYP2C9) zmanjšuje izpostavljenost aktivnemu presnovku za približno 50 %.
As observed for angiotensin converting enzyme inhibitors, losartan and the other angiotensin antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.
Tako kot so opazili pri zaviralcih angiotenzinske konvertaze, so tudi losartan in drugi antagonisti angiotenzina pri črncih očitno manj učinkoviti za zniževanje krvnega tlaka kot pri drugih rasah, verjetno zaradi večje pojavnosti nizkih vrednosti renina pri črnski populaciji hipertonikov.
The primary endpoint of the study was a composite endpoint of doubling of the serum creatinine endstage renal failure (need for dialysis or transplantation) or death.
Primarni opazovani dogodek v študiji je bil sestavljeni opazovani dogodek podvojitve kreatinina v serumu, končne ledvične odpovedi (potreba po dializi ali presaditvi) ali smrt.
Both losartan and its active metabolite are ≥99% bound to plasma proteins, primarily albumin.
Tako losartan kot njegov aktivni presnovek sta v ≥ 99 % vezana na plazemske proteine, predvsem na albumin.
If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
Pregnancy and Lactation
Nosečnost in dojenje
Co-administration of lithium and losartan should be undertaken with caution.
Sočasne uporabe litija in losartana se je treba lotiti previdno.
If you forget to take Cozaar
Če ste pozabili vzeti zdravilo Cozaar
Dosage in special patient groups
Odmerjanje pri posebnih skupinah bolnikov
[To be implemented nationally]
[Izpolni država članica]
Concomitant use of angiotensin II antagonists or diuretics and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Sočasna uporaba antagonistov angiotenzina II ali diuretikov in NSAR-ov lahko poveča tveganje za poslabšanje ledvične funkcije, vključno z možno akutno ledvično odpovedjo, ter poveča količino kalija v serumu, še posebej pri bolnikih z že obstoječim slabim delovanjem ledvic.
For the following individual and combined components of the primary endpoint, the results showed a significant risk reduction in the group treated with Losartan: 25.3 % risk reduction for doubling of the serum creatinine (p = 0.006); 28.6 % risk reduction for end-stage renal failure (p = 0.002); 19.9 % risk reduction for end-stage renal failure or death (p = 0.009); 21.0 % risk reduction for doubling of serum creatinine or end-stage renal failure (p = 0.01).
V skupini, ki se je zdravila z losartanom, se je pomembno zmanjšalo tveganje za naslednje posamezne komponente primarnega opazovanega dogodka in njihove kombinacije: 25,3 % zmanjšanje tveganja za podvojitev kreatinina v serumu (p = 0,006); 28,6 % zmanjšanje tveganja za končno ledvično odpoved (p = 0,002), 19,9 % zmanjšanje tveganja za končno ledvično odpoved ali smrt (p = 0,009), 21,0 % zmanjšanje tveganja za podvojitev kreatinina v serumu ali končno ledvično odpoved (p = 0,010).
Cozaar has been studied in children.
Zdravilo Cozaar so preizkušali pri otrocih.
After a majority voting at the CHMP plenum, the CHMP recommended that the following wording be proposed to reflect the data from the ELITE I and II studies, within a second-line indication: “Treatment of chronic heart failure (in patients aged 60 or over), when treatment with ACE inhibitors is not considered suitable due to incompatibility or contraindications.
Na svojem plenarnem zasedanju je CHMP z večino glasov priporočil, da se predlaga naslednje besedilo, odražajoče podatke iz študij ELITE I in II, v okviru indikacije kot druga izbira: „Zdravljenje kroničnega srčnega popuščanja (pri bolnikih, starih 60 let ali več), ko je zdravljenje z zaviralci ACE ocenjeno kot neprimerno zaradi nezdružljivosti ali kontraindikacij.
Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o., Šmartinska cesta 140, 1000 Ljubljana
Merck Sharp & Dohme, inovativna zdravila d.o.o., Šmartinska cesta 140, 1000 Ljubljana, Slovenija
Losartan belongs to a group of medicines known as angiotensin-II receptor antagonists.
Losartan spada v skupino zdravil, imenovanih "antagonisti receptorjev angiotenzina II".
Whilst the ELITE I indicated an reduction in risk of mortality due to heart failure in patients taking losartan, as compared to captopril, the ELITE II study was not powered to establish equal efficacy between losartan and captopril.
Medtem ko je preskušanje ELITE I nakazalo zmanjšanje tveganja smrtnosti zaradi srčnega popuščanja pri bolnikih, prejemajočih losartan, v primerjavi s kaptoprilom, študija ELITE II ni zmogla ugotoviti enake učinkovitosti med losartanom in kaptoprilom.
For patients with intravascular volume-depletion (e.g. those treated with high-dose diuretics), a starting dose of 25 mg once daily should be considered (see section 4.4).
Uporaba pri bolnikih z zmanjšanim intravaskularnim volumnom Pri bolnikih z zmanjšanim intravaskularnim volumnom (npr. tistih, ki se zdravijo z velikimi odmerki diuretikov) je treba razmisliti o začetnem odmerku 25 mg enkrat na dan (glejte poglavje 4.4).
About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite.
Približno 14 % intravenskega ali peroralnega odmerka losartana se pretvori v njegov aktivni presnovek.
In patients with heart failure, with or without renal impairment, there is - as with other drugs acting on the renin-angiotensin system - a risk of severe arterial hypotension, and (often acute) renal impairment.
Pri bolnikih s srčnim popuščanjem z okvaro ledvic ali brez obstaja, tako kot pri drugih zdravilih, ki delujejo na sistem renin-angiotenzin, tveganje za hudo arterijsko hipotenzijo in (pogosto akutno) ledvično okvaro.
If you experience dizziness or drowsiness, you should consult your doctor before attempting such activities.
Če ste omotični ali zaspani, se, preden se lotite teh aktivnosti, posvetujte z zdravnikom.
The efficacy and safety are well established for the indication “treatment of essential hypertension”.
Za indikacijo »zdravljenje esencialne hipertenzije« sta učinkovitost in varnost dobro potrjena.
In the ELITE Study carried out over 48 weeks in 722 patients with heart failure (NYHA Class II-IV), no difference was observed between the patients treated with Losartan and those treated with captopril was observed with regard to the primary endpoint of a long-term change in renal function.
V študiji ELITE, ki je trajala 48 tednov in je vključevala 722 bolnikov s srčnim popuščanjem (NYHA razred II-IV), niso opazili nobenih razlik v dolgoročni spremembi ledvične funkcije kot primarnem opazovanem dogodku med bolniki, ki so prejemali losartan, in bolniki, ki so prejemali kaptopril.
You must not take losartan if you are breast-feeding.
Losartana ne smete jemati, če dojite.
In a clinical study conducted in type 2 diabetic patients with nephropathy, 9.9% of patients treated with Losartan tablets developed hyperkalaemia >5.5 mEq/l and 3.4% of patients treated with placebo (see section 4.4, ‘Electrolyte imbalances').
V klinični študiji, izvedeni pri bolnikih s sladkorno boleznijo tipa 2 in z nefropatijo, se je hiperkaliemija > 5,5 mEq/l razvila pri 9,9 % bolnikov, ki so prejemali tablete z losartanom, in pri 3,4 % bolnikov, ki so prejemali placebo (glejte poglavje 4.4, "Elektrolitsko neravnovesje").
• feeling of increased heart rate (palpitations),
• občutek pospešenega bitja srca (palpitacije)
the CHMP has recommended the amendment of the Marketing Authorisations for which the Summary of Product Characteristics, labelling and package leaflet are set out in Annex III for Cozaar and associated names (see Annex I).
je CHMP priporočil dopolnitev dovoljenj za promet, za katera so povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo podani v Dodatku III za zdravilo Cozaar in z njim povezana imena (glejte Dodatek I).
Treatment with losartan, as compared with placebo, resulted in a 16.1% risk reduction in the number of patients reaching the primary composite endpoint.
Zdravljenje z losartanom je v primerjavi s placebom, z ozirom na število bolnikov, ki so dosegli sestavljeno primarno končno točko, privedlo do 16,1-odstotnega zmanjšanja tveganja.
The use of losartan is not recommended in patients with severe hepatic impairment (see section "Do not take losartan").
Uporabe losartana ne priporočamo za bolnike s hudo okvaro jeter (glejte poglavje "Ne jemljite zdravila Cozaar").
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION <{DD/MM/YYYY}> <{DD month YYYY}>
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET {DD/MM/LLLL}
Angiotensin II binds to the AT1 receptor found in many tissues (e.g. vascular smooth muscle, adrenal gland, kidneys and the heart) and elicits several important biological actions, including vasoconstriction and the release of aldosterone.
Angiotenzin II se veže na AT1 receptorje, ki se nahajajo v mnogih tkivih (npr. gladkih mišicah žil, nadledvični žlezi, ledvicah in srcu), in sproži več pomembnih bioloških učinkov, vključno z vazokonstrikcijo in s sproščanjem aldosterona.
All-cause mortality rate was not significantly different between the two treatment groups.
Celokupna smrtnost se med skupinama ni pomembno razlikovala.
• serum creatinine and serum potassium in patients with heart failure,
• povečana količina kreatinina in kalija v serumu pri bolnikih s srčnim popuščanjem
Cozaar and associated names (see Annex I) 12.5 mg film-coated tablets Cozaar and associated names (see Annex I) 25 mg film-coated tablets Cozaar and associated names (see Annex I) 50 mg film-coated tablets Cozaar and associated names (see Annex I) 100 mg film-coated tablets
Cozaar in povezana imena (glejte Dodatek I) 12,5 mg filmsko obložene tablete Cozaar in povezana imena (glejte Dodatek I) 25 mg filmsko obložene tablete Cozaar in povezana imena (glejte Dodatek I) 50 mg filmsko obložene tablete Cozaar in povezana imena (glejte Dodatek I) 100 mg filmsko obložene tablete
• severe chest pain (angina pectoris),
• huda bolečina v prsnem košu (angina pektoris)
In the LIFE study an additional benefit was noted with regards to stroke for the losartan based strategy, and effects were similar with regard to MI and CV mortality, indicating that the demonstrated beneficial effect of beta-blockade on CV morbidity and mortality in general was also present for losartan.
V študiji LIFE je bila za strategijo na podlagi losartana ugotovljena dodatna korist z vidika kapi, medtem ko so bili z vidika miokarnega infarkta in srčnožilne smrtnosti učinki podobni, nakazujoč, da je dokazani ugodni učinek blokade receptorjev beta na srčnožilno obolevnost in smrtnost nasploh prisoten tudi pri losartanu.
Losartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax which in turn lowers the blood pressure.
Losartan preprečuje vezavo angiotenzina II na te receptorje in tako povzroči, da se žile sprostijo in se krvni tlak zniža.